Thursday, 5 November 2026European Markets

FERM.CAS.MUN.CANNE And BAINS MER MONACO Have A High Dividend Yield And Return On Equity In The Resorts & Casinos Industry.

Loading stream...

(vianews) - ferm.cas.mun.canne (fcmc.pa) is among this list of stock assets with the highest dividend rate and return on equity on the resorts & casinos industry.

financial asset price forward dividend yield return on equity
ferm.cas.mun.canne (fcmc.pa) €1590.00 5% 3.89%
bains mer monaco (bain.pa) €103.00 1.22% 5.66%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ferm.cas.mun.canne (fcmc.pa)

5% forward dividend yield and 3.89% return on equity

société fermière du casino municipal de cannes operates casinos and hotels in france. the company operates 3 hotels with 565 rooms, suites, and cottages under the hôtel barrière le majestic, the hôtel barrière le gray d'albion, and the hôtel barrière le carl gustaf st-barth brands; and 2 casinos, including 350 slot machines and 38 games tables under the casino barrière croisette and casino barrière les princes brands. it also operates 8 restaurants, 9 bars, and 1 spa. the company was founded in 1919 and is based in cannes, france.

earnings per share

as for profitability, ferm.cas.mun.canne has a trailing twelve months eps of €60.1.

pe ratio

ferm.cas.mun.canne has a trailing twelve months price to earnings ratio of 26.46. meaning, the purchaser of the share is investing €26.46 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.89%.

yearly top and bottom value

ferm.cas.mun.canne's stock is valued at €1,590.00 at 17:40 est, way below its 52-week high of €1,810.00 and way higher than its 52-week low of €1,400.00.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 11, 2023, the estimated forward annual dividend rate is 77 and the estimated forward annual dividend yield is 5%.

more news about ferm.cas.mun.canne.

2. bains mer monaco (bain.pa)

1.22% forward dividend yield and 5.66% return on equity

société anonyme des bains de mer et du cercle des étrangers à monaco operates in the gaming, hotels, and rental sectors in monaco. the company operates casinos; hotels; restaurants; lounge bars and nightclubs; wellness and leisure facilities; shows and concert halls; shopping centers; and meetings and events centers. it is also involved in the slot machines, table games, and other activities; and rental of residential properties, boutiques, and offices. in addition, the company offers catering services. the company was incorporated in 1863 and is headquartered in monaco.

earnings per share

as for profitability, bains mer monaco has a trailing twelve months eps of €3.63.

pe ratio

bains mer monaco has a trailing twelve months price to earnings ratio of 28.37. meaning, the purchaser of the share is investing €28.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.66%.

dividend yield

according to morningstar, inc., the next dividend payment is on oct 10, 2023, the estimated forward annual dividend rate is 1.2 and the estimated forward annual dividend yield is 1.22%.

moving average

bains mer monaco's value is below its 50-day moving average of €105.58 and below its 200-day moving average of €104.64.

yearly top and bottom value

bains mer monaco's stock is valued at €103.00 at 17:40 est, way below its 52-week high of €115.00 and above its 52-week low of €98.20.

more news about bains mer monaco.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com